Nabriva Therapeutics PLC (STU:NTY)
€ 1.25 0.02 (1.63%) Market Cap: 2.76 Mil Enterprise Value: 1.62 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 39/100

Q2 2021 Nabriva Therapeutics PLC Earnings Call Transcript

Aug 05, 2021 / 08:30PM GMT
Release Date Price: €52.33
Operator

Good day, and thank you for standing by. Welcome to the Nabriva Therapeutics Second Quarter 2021 Financial Results Call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Mr. Dan Dolan, Chief Financial Officer. Please go ahead.

Daniel Dolan
Nabriva Therapeutics plc - CFO

Thank you, and good afternoon, everyone. Welcome to Nabriva's conference call and webcast where we will discuss the second quarter 2021 earnings and also provide a business update. Slides for today's presentation are posted on the company's website, www.nabriva.com, and can be found under the Investors tab in the Events and Presentations section. We recommend that you refer to the presentation as we'll be using those slides for today's discussion.

Before we begin on Slide 2, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot